ArticleFunctional & integrative genomics2025
Whole-Genome analysis of Bacillus subtilis MBBL2 genomic characterization and comparative genomics.
Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Whole-genome sequencing and comparative genomics reveal antimicrobial potential and adaptive traits of Bacillus velezensis AM12.Functional & integrative genomics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents the whole-genome sequencing and comprehensive analysis of Bacillus subtilis MBBL2, a strain isolated from soil samples in Lahore, Pakistan. The genome consists of 4,574,405 base pairs, with a GC content of 42.99%, and is assembled into 908 contigs. Using a range of bioinformatics tools, we performed genome assembly, functional annotation, secondary metabolite biosynthesis prediction, antimicrobial resistance (AMR) gene identification, and CRISPR array detection. The genome was initially assembled, achieving an average coverage of 126.534x, and its quality was also assessed to ensure completeness. Prokka was used to annotate 5,392 genes, including 5,033 protein-coding sequences, tRNAs, and rRNAs. Secondary metabolite biosynthesis clusters were identified revealing several important clusters involved in riboflavin, vitamin B6 biosynthesis, and antimicrobial peptide production via non-ribosomal peptide synthetase (NRPS). Notably, a novel bacteriocin gene cluster was detected, suggesting the strain's potential as a source of antimicrobial peptides. AMR genes were identified highlighting resistance to various antibiotics. CRISPR arrays were also analyzed indicating the strain's adaptive immune system. Genomic comparisons provided insights into the genetic diversity and evolutionary relationships of Bacillus subtilis strains. This study reveals the potential of B. subtilis MBBL2 as a probiotic in aquaculture, with applications in sustainable practices such as biocontrol. The findings contribute valuable genomic resources to the B. subtilis research community and open avenues for future biotechnological applications.
Indexed as
Identifiers
40802201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.